BioMarin Pharmaceutical Inc. - Common Stock (BMRN)
70.33
-0.69 (-0.97%)
Biomarin Pharmaceuticals is a biotechnology company that specializes in developing and commercializing innovative therapies for rare genetic disorders and critical diseases
The company focuses on creating treatments for patients with serious and life-threatening conditions, often targeting specific genetic mutations. Biomarin’s research and product development emphasize precision medicine, with a commitment to advancing therapeutic options and improving the quality of life for individuals affected by these rare diseases. Through its work, Biomarin strives to address unmet medical needs and enhance patient care through scientific innovation.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQSRPT) and its peers.
Shares of biotech company BioMarin Pharmaceutical (NASDAQBMRN)
jumped 9.6% in the pre-market session after the company reported impressive fourth-quarter results, exceeding analysts' sales and EPS estimates. Total revenue grew 16% y/y fueled by strong demand for Voxzogo, which saw a 42% jump in sales, and a steady 9% increase in its Enzyme Therapies segment. Improved profitability also played a key role, with GAAP net income soaring more than fivefold.
Looking ahead, management expects another year of double-digit revenue and earnings growth in 2025, with a projected 10% increase in total revenue at the midpoint of guidance.
Overall, the quarter reflected strong execution, with standout performances in key growth areas and clear momentum heading into the first half of 2025.
Biotech company BioMarin Pharmaceutical (NASDAQBMRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 15.6% year on year to $747.3 million. The company’s full-year revenue guidance of $3.15 billion at the midpoint came in 1.5% above analysts’ estimates. Its non-GAAP profit of $0.92 per share was 24.6% above analysts’ consensus estimates.
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.
NASDAQ:BMRN is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.
Take a closer look at BIOMARIN PHARMACEUTICAL INC , a remarkable value stock. NASDAQ:BMRN excels in fundamentals and maintains a very reasonable valuation.
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX, NVO, and BMRN.
